President Donald Trump announced a new wave of tariffs targeting pharmaceuticals, heavy trucks, and household furniture products.
These measures, set to take effect on October 1, 2025, are framed as efforts to protect American manufacturers from “unfair outside competition” and encourage domestic production. Trump detailed the plans in posts on Truth Social, emphasizing national security and economic reciprocity.
The announcements come amid ongoing trade tensions, with the U.S. already collecting over $200 billion in tariff revenues for 2025, including a record $31.4 billion in August. These tariffs build on Trump’s broader “reciprocal” trade strategy, invoked under laws like the International Emergency Economic Powers Act (IEEPA) and Section 232 of the 1962 Trade Expansion Act.
Earlier in 2025, he imposed baseline 10% tariffs on most imports, with escalations on China up to 30%, the EU 15-25% and others like Brazil additional 40%. Asian stocks fell on September 26, with pharmaceutical shares in Japan and China declining due to fears of supply chain disruptions.
Register for Tekedia Mini-MBA edition 19 (Feb 9 – May 2, 2026): big discounts for early bird.
Tekedia AI in Business Masterclass opens registrations.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Register for Tekedia AI Lab: From Technical Design to Deployment (next edition begins Jan 24 2026).
The Nikkei 225 dropped 0.87%. U.S. futures also dipped, reflecting concerns over inflation. While major firms have pledged U.S. expansions, critics warn of higher drug prices and shortages for non-exempt medicines.
The Pharmaceutical Research and Manufacturers of America (PhRMA) noted exemptions could limit damage but urged regulatory fixes over tariffs. Mexico faces the heaviest hit on trucks; furniture importers may pass costs to consumers, exacerbating price surges in home goods.
Tariffs have generated significant revenue, which Trump plans to partially redirect to farmers as transition aid—acknowledging short-term pain from retaliatory measures. Core inflation slowed to 0.2% in August, but overall prices are up 2.7% year-over-year, with warnings that new levies could push it higher.
Opponents, including the Taxpayers Protection Alliance, argue the tariffs act as a tax on U.S. consumers and businesses like Walmart, Home Depot, raising costs without fully addressing supply chains.
A Supreme Court case on the legality of IEEPA-based tariffs is pending, with arguments set for July 31, 2025—potentially upending the policy. Farmers, hit by lost exports, are set to receive bailout funds from tariff proceeds, a move Trump described as ensuring “they’ll be doing better than before.”
This escalation aligns with Trump’s campaign promises for aggressive trade enforcement, but it risks further retaliation from partners like China and the EU. The new tariffs, effective October 1, 2025, are projected to generate additional revenue for the U.S. government, building on the over $200 billion collected year-to-date from existing duties.
However, they risk exacerbating inflationary pressures, with economists warning of higher costs passed on to consumers and businesses. Core inflation, already at 0.2% in August, could rise as import-dependent sectors absorb the hikes.
The OECD notes that while global growth holds at 3.2% for 2025, supported by AI investments and U.S. fiscal aid, the full tariff shock remains unabsorbed, potentially slowing momentum.
The 100% tariff targets branded/patented drugs but spares generics and firms with U.S. plants under construction such as Eli Lilly’s $11.5B expansion. India’s generic exports major U.S. supplier face minimal hit, per Pharmexcil, but complex generics could see price pressures.
UBS deems the real-world impact “negligible” due to carveouts, though Brookings warns of generic shortages and patient rationing. Ireland’s pharma exports surged 536% YOY in anticipation, but EU firms like Roche push for talks to avoid patient harm.
IKEA calls it a blow to business; U.S. imports have flooded markets, hurting domestic makers in states like North Carolina. Homebuilders face compounded costs, worsening affordability crises. Shields U.S. firms like Peterbilt and Mack from Mexican competition, but the U.S. Chamber warns it endangers alliances with Canada, Japan, and Germany—no security threat posed.
Logistics firms may reroute supply chains, hiking costs. Global equities dipped post-announcement: Nikkei fell 0.87%, Japan’s pharma index 1%, Hong Kong’s 2.8%. U.S. futures were mixed, with investors viewing it as targeted rather than systemic.
Fed officials remain cautious on rate cuts amid tariff uncertainty. India’s MEA is “closely monitoring” pharma impacts, with exporters assessing complex generics. Australia’s health minister decries it as “unfair after 20 years of free trade.”
Mexico bears the brunt on trucks; EU seeks urgent talks. Past retaliations like China’s soybean halt suggest escalation, though trade deals cap some rates. A pending Supreme Court case on IEEPA legality could invalidate broad uses.
Proponents see job gains in manufacturing and reduced deficits, aligning with Trump’s reciprocity push. Critics, including the Taxpayers Protection Alliance, label it a “tax on Americans,” risking supply disruptions and higher premiums for 131M patients on key meds.
Overall, it accelerates U.S. reshoring but at the cost of global tensions and consumer burdens—echoing 2018-2019 trade wars.